GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Beneish M-Score

Organogenesis Holdings (Organogenesis Holdings) Beneish M-Score : -2.84 (As of Apr. 28, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.84 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Organogenesis Holdings's Beneish M-Score or its related term are showing as below:

ORGO' s Beneish M-Score Range Over the Past 10 Years
Min: -2.84   Med: -2.34   Max: -1.72
Current: -2.84

During the past 9 years, the highest Beneish M-Score of Organogenesis Holdings was -1.72. The lowest was -2.84. And the median was -2.34.


Organogenesis Holdings Beneish M-Score Historical Data

The historical data trend for Organogenesis Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Beneish M-Score Chart

Organogenesis Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -2.62 -1.80 -1.72 -2.53 -2.84

Organogenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -2.45 -2.54 -2.72 -2.84

Competitive Comparison of Organogenesis Holdings's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Beneish M-Score falls into.



Organogenesis Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Organogenesis Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9543+0.528 * 1.0171+0.404 * 0.9472+0.892 * 0.9606+0.115 * 0.8446
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9894+4.679 * -0.05658-0.327 * 0.9639
=-2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $82.0 Mil.
Revenue was 99.651 + 108.531 + 117.316 + 107.642 = $433.1 Mil.
Gross Profit was 71.882 + 82.742 + 91 + 81.035 = $326.7 Mil.
Total Current Assets was $225.0 Mil.
Total Assets was $460.0 Mil.
Property, Plant and Equipment(Net PPE) was $156.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $23.4 Mil.
Selling, General, & Admin. Expense(SGA) was $269.8 Mil.
Total Current Liabilities was $80.5 Mil.
Long-Term Debt & Capital Lease Obligation was $99.6 Mil.
Net Income was -0.568 + 3.167 + 5.316 + -2.969 = $4.9 Mil.
Non Operating Income was -0.025 + 0.031 + 0.028 + 0.023 = $0.1 Mil.
Cash Flow from Operations was 10.613 + 16.735 + 8.646 + -5.077 = $30.9 Mil.
Total Receivables was $89.5 Mil.
Revenue was 115.516 + 116.859 + 121.401 + 97.117 = $450.9 Mil.
Gross Profit was 88.406 + 90.682 + 94.749 + 72.037 = $345.9 Mil.
Total Current Assets was $222.6 Mil.
Total Assets was $449.4 Mil.
Property, Plant and Equipment(Net PPE) was $145.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $18.0 Mil.
Selling, General, & Admin. Expense(SGA) was $283.8 Mil.
Total Current Liabilities was $75.0 Mil.
Long-Term Debt & Capital Lease Obligation was $107.5 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(81.999 / 433.14) / (89.45 / 450.893)
=0.189313 / 0.198384
=0.9543

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(345.874 / 450.893) / (326.659 / 433.14)
=0.767087 / 0.754165
=1.0171

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (225.044 + 156.346) / 460.025) / (1 - (222.609 + 145.655) / 449.359)
=0.170936 / 0.180468
=0.9472

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=433.14 / 450.893
=0.9606

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.031 / (18.031 + 145.655)) / (23.449 / (23.449 + 156.346))
=0.110156 / 0.130421
=0.8446

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(269.754 / 433.14) / (283.808 / 450.893)
=0.622787 / 0.629435
=0.9894

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((99.64 + 80.509) / 460.025) / ((107.545 + 75.023) / 449.359)
=0.391607 / 0.406285
=0.9639

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(4.946 - 0.057 - 30.917) / 460.025
=-0.05658

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Organogenesis Holdings has a M-score of -2.84 suggests that the company is unlikely to be a manipulator.


Organogenesis Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Organogenesis Holdings (Organogenesis Holdings) Business Description

Traded in Other Exchanges
Address
85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Executives
Albert Erani 10 percent owner 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz 10 percent owner
Arthur S Leibowitz director 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney director, officer: President and CEO C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin director 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo officer: VP Health Policy & Contracting C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin director 7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf director, 10 percent owner
Alan A. Ades director, 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021

Organogenesis Holdings (Organogenesis Holdings) Headlines